



Senzime establishment and first TetraGraph-system order in Germany

Press release: Uppsala, January 14, 2021. Senzime AB (publ) today announces the establishment of a German subsidiary, the recruitment of a Country Manager and the first TetraGraph-system order from the University clinic Katholisches Klinikum Bochum.

Senzime is now establishing a direct sales organization in Germany through Senzime GmbH and has recently recruited a local Country Manager as well as a Regional Clinical Manager. The German organization will be up and running from February this year.

"With this initial order we kick-start our direct sales in Germany, Europe's largest medical device market with a population of 81 million people and more than 2 000 hospitals", says Pia Renaudin, CEO at Senzime.

The University clinic Katholisches Klinikum Bochum is located right in the heart of the Ruhr Region and has over 240 000 patients annually and more than 1 600 beds. Their evaluation of the TetraGraph has now resulted in this first order with the intention to substitute all existing monitors at the hospital. Several studies are expected from the hospital following these purchases, evidencing patient outcome using TetraGraph.

"Monitoring muscle relaxation in patients under general anesthesia is of great importance for patient safety. We are scientifically investigating the reliability of the available clinical measurement methods, and we are convinced that the electromyography technique used by the TetraGraph is more reliable than acceleromyography based on our ongoing studies", says Prof. Dr. Thomas Weber, Direktor Anästhesiologie und Intensivmedizin

Senzime's TetraGraph neuromuscular monitor is a unique digital system designed to address the needs of perioperative monitoring of physiologic data in surgical patients receiving general anesthesia and muscle relaxation using neuromuscular blocking drugs (NMBAs). The TetraGraph stimulates a peripheral nerve and measures, analyzes and displays in real-time the muscle function.

For further information, please contact:

Pia Renaudin, CEO of Senzime AB

Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com

TO THE EDITORS

About Senzime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se is Certified Adviser for Senzime. www.senzime.com

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on January 14, 2021, 21:45 CET.